Skip to main
DTIL
DTIL logo

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences Inc. is witnessing encouraging developments in its product pipeline, particularly with the PBGENE-HBV program, which may enhance the credibility of its ARCUS platform and de-risk its broader pipeline. Initial promising clinical data from the ECUR-506 trial indicates preliminary validation of in vivo ARCUS editing and suggests a positive safety profile, potentially benefiting further gene editing initiatives. Additionally, the favorable risk/reward outlook is supported by strong preclinical results and the company’s current valuation, which is substantially below its net cash position, providing a solid foundation for future growth opportunities.

Bears say

Precision BioSciences Inc. faces significant financial risks that contribute to a negative outlook on its stock. The company operates in a nascent gene editing sector, where regulatory hurdles and lengthy clinical trial processes could hinder product development timelines and impede potential revenue generation. Furthermore, reliance on intellectual property poses challenges, as litigation or competition may adversely affect its innovation pipeline and market positioning, compounding the risks of lower-than-expected sales impacting the company's financial performance.

Precision Biosciences (DTIL) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Buy based on their latest research and market trends.

According to 9 analysts, Precision Biosciences (DTIL) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.